T. Rowe Price Health Sciences Fund (PRHSX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks long-term capital appreciation. The fund will normally invest at least 80% of its net assets (including any borrowings for investment purposes) in the common stocks of companies engaged in the research- development- production- or distribution of products or services related to health care- medicine- or the life sciences (collectively termed "health sciences"). While the fund can invest in companies of any size- the majority of fund assets are expected to be invested in large- and mid-capitalization companies.


1 month+1.62% 3 years+6.23%
3 months+6.45% 5 years+19.31%
1 year+20.62% Since inception+14.69%
Data through --

Peer Comparisonvs. Health

Performance 5-yr return+19.31%+17.28%
Expense ratio0.77%1.30%
Risk 5 year sharpe ratio1.211.02
Net assets$12.0B$3.1B
Average market cap$25.4B$10.4B
Average P/E26.422.9
Portfolio turnover38%38%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyT. Rowe Price
Fund manager & tenureZiad Bakri / 1 Years
Minimal initial investment$2,500.00
Minimum IRA investment$1,000.00


U.S. stock95.18%
International stock3.99%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 93.76%
Industrial materials 0.91%
Consumer service 0.89%
Financial service 0.38%
Telecommunication 0.19%
Top 10 Holdings
Portfolio weighting
UNH UnitedHealth6.99%
BDX Becton Dickinson and Co4.31%
ISRG Intuitive Surgical4.02%
VRTX Vertex Pharmaceuticals Inc3.29%
CI Cigna Corp2.95%
SAGE SAGE Therapeutics Inc2.49%
ANTM WellPoint2.34%
SYK Stryker Corp2.33%
A Agilent Technologies Inc2.26%
ALXN Alexion Pharmaceuticals Inc2.21%